Drugs / DA5221-B2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06290349 Background | Apr 2024 → Sep 2025 overdue | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA5221-B2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06290349 ↗ |
| Action | Inhibit | “the DPP-4 inhibitor DA5221-B2” NCT06290349 ↗ |
| Route | Oral | “DA5221-B2, orally, daily for background therapy” NCT06290349 ↗ |